Novartis buys Myricx Bio in $1.5bn deal
Swiss drug and health care company Novartis has acquired London based biotech Myricx Bio in a deal valued at up to $1.5bn Announced on July 6, the deal comprises a substantial $1.1bn upfront cash payment and $400 million in potential milestones. The transaction is expected to close in the second half of 2026, subject to customary regulatory approvals. Myricx Bio…